We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




New At-Home Cervical Cancer Screening Device to Increase Accessibility for Patients

By LabMedica International staff writers
Posted on 05 Jun 2025

Cervical cancer is typically linked to certain types of human papillomavirus (HPV), which is passed through sexual contact. More...

While many people are infected with HPV, only a small percentage will develop cervical cancer. Still, screenings are crucial in detecting HPV, cells that may develop into cancer, and cancer. Early intervention is key to saving lives. However, a significant number of cervical cancer diagnoses occur in individuals who haven’t been screened in the previous five years, highlighting a critical access issue in preventive care. Now, researchers have validated a new at-home self-collection device for cervical samples, which has received FDA approval and is shown to be both safe and effective in detecting cervical cancer with high accuracy.

The research, led by the University of Colorado School of Medicine (Aurora, CO, USA), was part of the SELF-CERV trial, a nationwide clinical study involving over 600 participants. The trial was conducted across 16 medical sites in the U.S. and aimed to validate the performance of Teal Wand, which enables individuals to collect cervical cell samples from home by following instructions provided in a mailed kit. These samples are then sent to a lab for analysis. Participants in the trial also underwent traditional in-clinic exams to allow direct comparison of effectiveness. The device not only proved to be easy to use—90% of users completed collection in under five minutes—but it also helped overcome common barriers such as scheduling conflicts, discomfort with pelvic exams, and financial concerns.

Findings revealed that 86% would be more likely to keep up with cervical cancer screening if they could do so at home, and more than 90% preferred the self-collection method offered by the Teal Wand. Survey responses showed that 32% had delayed screenings due to a lack of time, 32% because of discomfort with exams, and another 32% due to financial concerns. The convenience and privacy of the at-home collection method helped mitigate these issues. Beyond increasing screening compliance, the Teal Wand could also benefit physicians and healthcare systems. Physicians can focus on broader aspects of patient health during appointments, confident in the reliability of the self-collection method. This could ultimately lead to earlier detection, fewer missed diagnoses, and a decrease in cervical cancer incidence nationwide.

“Overall, we wanted to make sure that a device like this lived up to the reliability a patient could expect in-clinic,” said Christine Conageski, MD, MSc, the principal investigator for the SELF-CERV trial. “Now, we’ll look at some implementation science and figure out how to integrate this technology into systems across the country, maybe even starting here in Colorado.”

Related Links:
CU School of Medicine


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Serological Pipet Controller
PIPETBOY GENIUS
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit
New
HAV Rapid Test
OnSite HAV IgG/IgM Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: INDICAID HPV Urine Test can detect 14 types of high-risk HPV using patented urine DNA concentration technology (Photo courtesy of PHASE Scientific)

World’s First Urine-Based HPV Test to Transform Cervical Cancer Screening

Human papillomavirus (HPV) is a very common sexually transmitted infection (STI) that causes more than 95% of cervical cancer cases. Detection of HPV infections that lead to cellular transformation, followed... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.